Bristol-Myers Squibb Company (ETR: BRM)
Germany
· Delayed Price · Currency is EUR | Market Cap | 102.87B |
| Revenue (ttm) | 42.53B |
| Net Income (ttm) | -6.51B |
| Shares Out | n/a |
| EPS (ttm) | -3.21 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | 2.20 (4.34%) |
| Ex-Dividend Date | Oct 4, 2024 |
| Volume | 3,385 |
| Open | 51.34 |
| Previous Close | 52.49 |
| Day's Range | 50.56 - 51.60 |
| 52-Week Range | 36.42 - 53.15 |
| Beta | 0.46 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 31, 2024 |
About BRM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esop... [Read more]
Financial Performance
In 2023, BRM's revenue was $45.01 billion, a decrease of -2.50% compared to the previous year's $46.16 billion. Earnings were $8.03 billion, an increase of 26.84%.
Financial numbers in USD Financial StatementsNews
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
JMP Securities initiated coverage on Summit Therapeutics Inc. (NASDAQ: SMMT), noting the company’s initial focus on infectious disease. Later, in 2022, the company pivoted to oncology and in-licensed...
How Is The Market Feeling About Bristol-Myers Squibb?
Bristol-Myers Squibb's (NYSE: BMY) short percent of float has risen 12.12% since its last report. The company recently reported that it has 22.50 million shares sold short , which is 1.11% of all reg...
Bristol-Myers Squibb's Cobenfy Shows Sustained Efficacy in Schizophrenia Treatment
Bristol-Myers Squibb's Cobenfy Shows Sustained Efficacy in Schizophrenia Treatment
Bristol Myers Squibb Stock Gets Relative Strength Rating Upgrade
Bristol Myers Squibb shows rising price performance, earning an upgrade to its IBD Relative Strength Rating
Bristol Myers Squibb Expects New Schizophrenia Treatment To Boost Long-Term Growth, Analysts Remain Cautious
On Thursday, Bristol Myers Squibb & Co (NYSE: BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of $11.28 billion, an increase of 8% year-over-year, or 10% when adjusted for...
Bristol Myers Squibb Presents New Long-term Data from the EMERGENT Program Evaluating COBENFY (xanomeline and trospium chloride) in Adults with Schizophrenia at Psych Congress 2024
Bristol Myers Squibb (NYSE: BMY) today announced new topline results from the Phase 3 EMERGENT-4 and EMERGENT-5 open-label trials evaluating the long-term efficacy, safety, and tolerability of COBENFY...
Bristol-Myers Squibb Company (BMY) Q3 2024 Earnings Call Transcript
Bristol Myers Squibb (BMY) Q3 2024 Earnings Call Transcript
BMY earnings call for the period ending September 30, 2024.
Bristol Myers Squibb Boosts 2024 Outlook On Strong Demand For Blood Thinner Med, New Drugs Drive Q3 Profit
On Thursday, Bristol Myers Squibb & Co (NYSE: BMY) posted third-quarter revenues of $11.89 billion, beating the consensus of $11.28 billion, an increase of 8% year-over-year, or 10% when adjusted for...
Key metrics from Bristol Myers Squibb’s (BMY) Q3 2024 earnings results
Bristol Myers Squibb (NYSE: BMY) reported its third quarter 2024 earnings results today. Total revenues increased 8% year-over-year to $11.9 billion. Revenues grew 10%, excluding FX. Net earnings attr...
Bristol Myers Earnings Top Q3 Estimates; Pharma Giant Raises Guidance
Bristol Myers earnings modestly beat Q3 estimates. The pharma giant also raised guidance. Bristol Myers stock edged higher Thursday.
Bristol Myers earnings top estimates and company raises guidance
Bristol Raises Guidance on Demand for Eliquis, New Drugs
Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by demand for the blood-thinner Eliquis and several newer treatments.
Bristol Myers Squibb tops earnings estimates and hikes outlook, helped by Eliquis and new drugs
The pharmaceutical giant also raised its full-year revenue forecast to an increase of more than 5%.
Bristol Myers Squibb Reports Third Quarter Financial Results for 2024
Bristol Myers Squibb (NYSE: BMY) today reports results for the third quarter of 2024. “We made important strides in the third quarter with the landmark U.S. approval of Cobenfy in schizophrenia, conti...
Bristol Myers Squibb Q3 2024 Earnings Preview: Profit decline anticipated
Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
Bristol Myers Squibb (NYSE: BMY) today announced that new clinical and health economics and outcomes research data (HEOR) from its neuropsychiatry portfolio evaluating COBENFY (xanomeline and trospium...
Bristol Myers Squibb's Q3 Earnings Are Likely To Be Strong
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
Financial giants have made a conspicuous bearish move on Bristol-Myers Squibb. Our analysis of options history for Bristol-Myers Squibb (NYSE: BMY) revealed 12 unusual trades. Delving into the detail...
Evotec & Bristol Myers Squibb Boost Proteomics Partnership Expansion
Evotec and Bristol Myers Squibb are strengthening their alliance to explore molecular glue degraders beyond cancer, aiming to unlock new therapeutic possibilities and address unmet medical needs. Jetz...
EQS-News: Evotec and Bristol Myers Squibb expand proteomics partnership
EQS-News: Evotec SE / Key word(s): Miscellaneous Evotec and Bristol Myers Squibb expand proteomics partnership 23.10.2024 / 07:29 CET/CEST The issuer is solely responsible for the content of this anno...
Citi on Cipla: Maintains Buy rating, expects 15.1% upside in share price
Citi has maintained its “Buy” rating on Cipla, with a target price of ₹1,870. With the current market price at ₹1,623.90, this implies an upside potential of approximately 15.1%. The brokerage noted t...
Hap Sneddon's Past Picks: Bristol-Myers Squibb, Chemtrade Logistics Income Fund, and Arista Networks
Hap Sneddon, president & chief portfolio manager at Castlemoore, discusses his past picks: Bristol-Myers Squibb, Chemtrade Logistics Income Fund, and Arista Networks.
CK Life’s new CEO counts on Big Pharma experience to boost new drug success, earnings
Lance Yuen spent two decades at Bristol-Myers Squibb and Bayer in the region before becoming the CEO at CK Life Sciences last month.